Market revenue in 2023 | USD 4.1 million |
Market revenue in 2030 | USD 9.1 million |
Growth rate | 12% (CAGR from 2023 to 2030) |
Largest segment | Biopharmaceutical processing |
Fastest growing segment | Other Applications |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Biopharmaceutical Processing, Other Applications |
Key market players worldwide | Thermo Fisher Scientific Inc, Merck KGaA, Agilent Technologies Inc, Promega, New England Biolabs, RayBiotech, Qiagen NV, Takara Bio Inc, Abnova, Worthington Enterprises Inc, MyBiosource, Sino Biological, Biovision, Calzyme, ArcticZymes Technologies, MBL International Corporation, BPS Bioscience Inc., Bio-Techne Corp, ABclonal |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to dnases market will help companies and investors design strategic landscapes.
Biopharmaceutical processing was the largest segment with a revenue share of 82.93% in 2023. Horizon Databook has segmented the Australia dnases market based on biopharmaceutical processing, other applications covering the revenue growth of each sub-segment from 2018 to 2030.
Horizon Databook provides a detailed overview of country-level data and insights on the Australia dnases market, including forecasts for subscribers. This country databook contains high-level insights into Australia dnases market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account